Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26046937 | 0.92 | ACSS2 (0.49) | ACSS2NAMPTKDM1AALDH1A1SCD | |
| SCHEMBL23843489 | 0.81 | ACSS2 (0.62) | ACSS2NAMPTKDM1A | |
| SCHEMBL26046925 | 0.78 | ACSS2 (0.42) | ACSS2NAMPTKDM1AALDH1A1SCD | |
| SCHEMBL26047747 | 0.78 | ACSS2 (0.41) | ACSS2NAMPTKDM1AALDH1A1SCD | |
| SCHEMBL26047616 | 0.78 | ACSS2 (0.42) | ACSS2NAMPTKDM1AALDH1A1SCD | |
| SCHEMBL26046919 | 0.76 | ACSS2 (0.43) | ACSS2ALDH1A1RAB9A | |
| SCHEMBL26046895 | 0.76 | ACSS2 (0.42) | ACSS2NAMPTKDM1AALDH1A1SCD | |
| SCHEMBL23843567 | 0.76 | ACSS2 (0.69) | ACSS2 | |
| SCHEMBL26047660 | 0.76 | ACSS2 (0.42) | ACSS2NAMPTKDM1AALDH1A1SCD | |
| SCHEMBL26046810 | 0.76 | SCD (0.45) | ACSS2NAMPTKDM1AALDH1A1SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | BRCA1, HRAS, PCNA | ACSS2 201/4885NAMPT 657/4885KDM1A 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.